Polypyrimidine Tract Binding Protein: A Universal Player in Cancer Development

Elizabeth Gonzalez; Terrie G Flatt; Midhat Farooqi; Lisa Johnson; Atif A Ahmed

doi:10.2174/0115665240251370231017053236

Polypyrimidine Tract Binding Protein: A Universal Player in Cancer Development

Curr Mol Med. 2023 Oct 24. doi: 10.2174/0115665240251370231017053236. Online ahead of print.

Authors

Elizabeth Gonzalez¹, Terrie G Flatt¹, Midhat Farooqi², Lisa Johnson³, Atif A Ahmed³

Affiliations

¹ Pediatric Hematology Oncology, Children Mercy Hospital, Kansas City, Missouri.
² Pathology, Children's Mercy Hospital, Kansas City, Missouri.
³ Seattle Children's Hospital/University of Washington, Seattle, Washington, USA.

PMID: 37877563
DOI: 10.2174/0115665240251370231017053236

Abstract

Objectives: Polypyrimidine tract binding protein is a 57-Kda protein located in the perinucleolar compartment where it binds RNA and regulates several biological functions through the regulation of RNA splicing. Numerous research articles have been published that address the cellular network and functions of PTB and its isoforms in various disease states.

Methodology: Through an extensive PubMed search, we attempt to summarize the relevant research into this biomolecule.

Results: Besides its roles in embryonic development, neuronal cell growth, RNA metabolism, apoptosis, and hematopoiesis, PTB can affect cancer growth via several metabolic, proliferative, and structural mechanisms. PTB overexpression has been documented in several cancers where it plays a role as a novel prognostic factor.

Conclusion: The diverse carcinogenic effect opens an argument into its potential role in inhibitory targeted therapy.

Keywords: PNC; Polypyrimidine tract binding protein; RNA splicing; cancer.